Key Highlights
- The stock traded at USD 4.39, down USD 0.6100, on Volume of only 15.1K shares.
- Cash and equivalents were about USD 20.0 million at June 30, 2026, up from USD 7.2 million at December 31, 2025.
- The second-quarter 2026 net loss was about USD 2.6 million, or USD 0.37 per share, against USD 2.4 million a year earlier.
- A private Placement closed on May 5, 2026 raised about USD 22.5 million gross and USD 20.7 million net.
- Management targets in-licensing or acquiring one or more Assets by December 31, 2026.
What Moved the Stock Today (down USD 0.6100, 12.20%)
CNS Pharmaceuticals (NASDAQ:CNSP) was down 12.20% to USD 4.39 in regular trading on November 3, 2026. That implies a Monday November 2, 2026 close of about USD 5.00 (calculated). Volume was light at 15.1K shares, and the screen shows a Market Capitalisation of about USD 6.42 million.
No company press release, 8-K or other announcement dated between October 30 and November 3, 2026 was identified. The most recent company news found was from early September 2026, when management appeared at investor events to describe its strategy. With so few shares changing hands, a handful of orders can shift the price by double digits, so the move looks more like a thin-liquidity pullback than a reaction to news.
The Latest Company Updates
The latest dated financial disclosure is the second-quarter 2026 report released on August 12, 2026. Net loss was about USD 2.6 million, or USD 0.37 per basic and diluted share, compared with about USD 2.4 million, or USD 6.42 per share, in the second quarter of 2025.
Research and development expenses were about USD 1.2 million, flat on the prior-year quarter. General and administrative expenses rose to about USD 1.5 million from about USD 1.2 million, mainly because of higher headcount-related costs, partly offset by lower professional services spending.
The company also said its global glioblastoma trial of Berubicin has completed enrollment and treatment, and that it is closing out the study while holding out-licensing discussions for Berubicin and a second candidate, TPI 287.
Business Background and Strategy
CNS Pharmaceuticals is a clinical-stage biotechnology company that began with a focus on brain cancer, led by Berubicin for glioblastoma. In March 2026 it announced a new corporate strategy aimed at building a diversified neurology and oncology pipeline, and appointed a new management team including a chief medical officer.
Funding for that plan came from a private placement announced on May 4, 2026 and closed on May 5, 2026. Gross proceeds were about USD 22.5 million, with about USD 20.7 million net. By comparison, cash was only about USD 2.95 million at March 31, 2026, and the first-quarter net loss was about USD 4.94 million. The company said cash should fund operations beyond the next twelve months.
Balance Sheet and Risks
The company reported 1,461,449 common shares outstanding and about 10.6 million shares on a fully diluted basis, including pre-funded warrants. The warrants can be exercised into a far larger float, which could dilute existing holders.
As a penny stock, CNSP carries elevated volatility, thin Liquidity and dilution risk. The Business has no marketed product, so its value rests on how it deploys cash and whether it completes an asset deal. A transaction that disappoints, or any further Equity raise, could weigh on the shares.
What to Watch Next
The key marker is the third-quarter 2026 report, normally due in mid-November, which will show the cash balance after another quarter of spending. Any announcement of an in-licensed or acquired asset, and any update on out-licensing Berubicin or TPI 287, would be the most direct company catalysts.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...